about
Selective block of the human 2-P domain potassium channel, TASK-3, and the native leak potassium current, IKSO, by zincDominant negative effects of a non-conducting TREK1 splice variant expressed in brain.What are the roles of the many different types of potassium channel expressed in cerebellar granule cells?Neuronal ion channels and their sensitivity to extremely low frequency weak electric field effects.Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability.Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels.Gating of two pore domain potassium channels.Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain.Recovery of current through mutated TASK3 potassium channels underlying Birk Barel syndrome.Enhancement of TWIK-related acid-sensitive potassium channel 3 (TASK3) two-pore domain potassium channel activity by tumor necrosis factor α.Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide.The M1P1 loop of TASK3 K2P channels apposes the selectivity filter and influences channel function.The in vivo contributions of TASK-1-containing channels to the actions of inhalation anesthetics, the alpha(2) adrenergic sedative dexmedetomidine, and cannabinoid agonists.TASK-3 two-pore domain potassium channels enable sustained high-frequency firing in cerebellar granule neurons.Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3.Map positions of SFR genes in relation to other freezing-related genes of Arabidopsis thaliana.GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K2P ) channel opener, reduces rat dorsal root ganglion neuron excitability.TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications.Modifying the subunit composition of TASK channels alters the modulation of a leak conductance in cerebellar granule neurons.Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol.Activation of TREK currents by riluzole in three subgroups of cultured mouse nodose ganglion neurons.Characterisation and regulation of wild type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertensionA comparison of the in-vitro activity of amphotericin B with that of liposomal amphotericin B against Candida albicans colonising central venous cathetersG(alpha)q-mediated regulation of TASK3 two-pore domain potassium channels: the role of protein kinase CInfluence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channelsTHE CONCISE GUIDE TO PHARMACOLOGY 2019/20: TransportersTHE CONCISE GUIDE TO PHARMACOLOGY 2019/20: EnzymesTHE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channelsTHE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptorsTHE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptorsTHE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptorsTHE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein TargetsEffects of the ventilatory stimulant, doxapram on human TASK-3 (KCNK9, K2P9.1) channels and TASK-1 (KCNK3, K2P3.1) channelsPharmacologically reversible, loss of function mutations in the TM2 and TM4 inner pore helices of TREK-1 K2P channels
P50
Q24677049-BEBDE6B2-3822-4C04-8E96-517B529F1B92Q34121562-EA6F2250-91CB-4431-8CC0-21A914727F08Q35185504-F5CB6551-4599-4064-A5C5-FB243E4C69B9Q35613528-E20713F1-86D7-4B3B-B373-EDCA818CC958Q36367146-A59C4EC8-BE0B-4DD1-9FD1-69961734CA91Q36830145-6627533A-1A3E-49E8-83AC-32118E3B80F0Q37766696-FBD53ADA-C393-4D34-8D26-744C24B1A145Q38270913-B48F56AA-9FF4-47E9-92B2-55BA3CBB1CFBQ39042858-F4EF62ED-286A-4E76-BDEC-68753DFFD262Q39048705-22944101-B3DB-420D-9AB6-49C01586B99CQ40082919-D55A46E4-EFE9-4710-AAFC-2F215E6256C2Q46640857-91325361-78E7-4673-BD59-850B4575E910Q46882556-CA7F4AA4-F46A-41A6-BD9D-455957B2B986Q47837775-8EB5EA83-5328-40F0-800E-C32935A3DC20Q47839162-2A46BF2B-14BA-4699-A68A-6A34CB248B66Q47971665-BB7D82C4-670D-4497-BFC6-F3B3D945BF01Q48278693-AE2DF788-D00E-4E98-BA7A-88D21A2E064FQ48331371-65F1D7DF-72D3-4D4C-A930-93BB07CB1CA6Q50747620-6D950CED-87A2-404B-A3C0-D9800BBBB386Q53837416-4FF1B9CA-265E-40B2-9D48-07E4F2F27BE7Q55439672-5433F5A7-05FB-4453-A5B2-3EA3A4BA6FB4Q58546159-29FE4F58-3416-4152-AA8B-8E3E2AA730ABQ72131958-FC83FDE8-6868-4B3A-ABD8-2DEE67989F83Q79996748-7AE47265-93E8-48E6-93BE-296E8E2859A6Q87257976-E8A719DA-AED8-4C98-9408-2179C1AC63B0Q91226578-7925940B-F2A9-4123-81F8-93B290DABA99Q91226583-A77384B2-2BAF-4988-9495-2741EF75BD67Q91226585-EE215706-FBAF-49F1-A991-FB9EACC75097Q91226587-5A487A3C-4EAE-41E0-A60A-2A435D54B57BQ91226591-626321BD-0000-4375-81AA-B3B60EA3DFA8Q91226594-973D7869-A610-4B17-B632-3B3B686D7BB3Q91226596-CD12C349-B7FA-4523-B3B1-D74EA7805F74Q92687705-3D75EDC6-9AD3-4671-800A-C4B03489E11AQ92913565-03D3BBF6-9F70-4892-A9A5-46B1B5FF4B66
P50
description
biochemicus
@nl
biochemistry researcher
@en
name
Emma L Veale
@es
Emma L Veale
@nl
Emma L Veale
@sl
Emma L. Veale
@en
type
label
Emma L Veale
@es
Emma L Veale
@nl
Emma L Veale
@sl
Emma L. Veale
@en
altLabel
Emma Veale
@en
prefLabel
Emma L Veale
@es
Emma L Veale
@nl
Emma L Veale
@sl
Emma L. Veale
@en
P106
P1153
6506604823
P21
P31
P496
0000-0002-6778-9929